Daniel M. Hausman
#5,081
Most Influential Person Now
American philosopher
Daniel M. Hausman's AcademicInfluence.com Rankings
Daniel M. Hausmanphilosophy Degrees
Philosophy
#450
World Rank
#929
Historical Rank
#210
USA Rank
Logic
#10285
World Rank
#13181
Historical Rank
#1932
USA Rank
Download Badge
Philosophy
Daniel M. Hausman's Degrees
- PhD Philosophy Columbia University
- Bachelors Philosophy Swarthmore College
Similar Degrees You Can Earn
Why Is Daniel M. Hausman Influential?
(Suggest an Edit or Addition)According to Wikipedia, Daniel M. Hausman is an American philosopher. His research has focused primarily on methodological, metaphysical, and ethical issues at the boundaries between economics and philosophy. He is currently Herbert A. Simon Professor Emeritus in the Department of Philosophy at the University of Wisconsin–Madison.
Daniel M. Hausman's Published Works
Published Works
- Sargramostim for active Crohn's disease. (2005) (284)
- Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection (2010) (251)
- Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. (2008) (180)
- A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors (2012) (160)
- A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins (2013) (145)
- Phase II study of PX-866 in recurrent glioblastoma. (2012) (102)
- Interleukin 21: combination strategies for cancer therapy (2008) (82)
- A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. (2015) (77)
- A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. (2015) (67)
- Interferon Lambda as a Potential New Therapeutic for Hepatitis C (2009) (65)
- Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. (2018) (63)
- A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours (2013) (57)
- Phase 1 b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection (2010) (46)
- Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non–Hodgkin's Lymphoma (2008) (41)
- A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer (2014) (39)
- Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. (2010) (36)
- Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers (2019) (27)
- A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. (2016) (26)
- A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck (2014) (22)
- 643 PEG-IFN-l: ANTIVIRAL ACTIVITY AND SAFETY PROFILE IN A 4-WEEK PHASE 1B STUDY IN RELAPSED GENOTYPE 1 HEPATITIS C INFECTION (2009) (22)
- Interleukin 21: combination strategies for cancer therapy (2008) (19)
- Phase 1 dose escalation of ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers. (2017) (13)
- Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers. (2017) (12)
- Efficacy and safety of recombinant interleukin-21 (rIL-21) and rituximab in relapsed/refractory indolent lymphoma (2008) (11)
- Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic (2013) (8)
- NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC). (2013) (8)
- 942 VIRAL KINETIC MODELING DURING TREATMENT WITH INTERFERON LAMBDA-1A IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (2009) (8)
- PX-866 and docetaxel in patients with advanced solid tumors. (2012) (7)
- Recombinant Interleukin-21 Plus Rituximab: Clinical Activity in a Phase 1, Dose-Finding Trial in Relapsed Low-Grade B Cell Lymphoma. (2007) (7)
- Recombinant IL-21 (rIL-21) in combination with sorafenib: Interim results from a phase 1/2 study in patients with metastatic renal cell cancer (mRCC) (2008) (6)
- 788 PEG-INTERFERON LAMBDA (PEG-IL-29): TRANSLATION OF IN VITRO PRECLINICAL DATA TO CLINICAL RESULTS (2008) (5)
- 255PPhase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers (2017) (4)
- IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone. (2015) (4)
- Abstract 652: PI3K inhibition combined with either cetuximab or docetaxel in a direct patient tumor model of HPV-positive and negative head and neck cancers (2011) (3)
- Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results. (2016) (3)
- Phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations. (2022) (2)
- Abstract A170: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and docetaxel. (2011) (1)
- 366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase (2010) (1)
- Repeated Cycles of Sargramostim for Active Crohnʼs Disease (CD): Update from an Open Label Trial (N.O.V.E.L. 5) (2005) (1)
- Ameloration of DSS-induced acute and chronic colitis by GM-CSF (2003) (1)
- Abstract B152: Clinical pharmacokinetics of an improved tablet formulation of ONT-380 in HER2+ metastatic breast cancer patients (2015) (0)
- Abstract P5-20-06: Phase 1 dose escalation with ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-high breast cancer (BC) (2018) (0)
This paper list is powered by the following services:
Other Resources About Daniel M. Hausman
What Schools Are Affiliated With Daniel M. Hausman?
Daniel M. Hausman is affiliated with the following schools: